将「宿主反应」范式从脓毒症扩展至心源性休克:证据、局限与机会
该综述指出,心源性休克(CS)的临床与研究努力主要集中于恢复低心输出量状态,但这一策略未能转化为结局改善,死亡率长期维持在30-50%。作者认为需要更好地刻画CS的病理生物学,以理解其表现与治疗效应的异质性并识别新治疗靶点。尽管脓毒症等其他危重症综合征已有数据,CS中失调的炎症与免疫的作用迄今描述甚少。高维分子分型,尤其白细胞转录组学,可能有助于刻画具有共同免疫失调机制的患者亚组。作者提出识别CS分子亚型可丰富未来临床试验设计并促进新疗法的发现。
要点
- 心源性休克死亡率长期维持在30-50%,聚焦恢复低心输出量的策略未能转化为结局改善。
- CS的病理生物学刻画不足,表现与治疗效应存在异质性,需要识别新治疗靶点。
- 脓毒症中失调炎症与免疫已有数据,但CS中该作用迄今描述甚少。
- 高维分子分型(尤其白细胞转录组学)可能识别具有共同免疫失调机制的CS亚组。
- 作者提出识别CS分子亚型可丰富未来临床试验设计并促进新疗法发现。
适用人群与场景
- 心源性休克(CS)患者
研究设计与关键结果
- 综述指出,CS的临床与研究努力主要集中于恢复低心输出量状态,但未能转化为结局改善,死亡率长期维持在30-50%。
- 作者描述高维分子技术(尤其白细胞转录组学)可用于识别CS分子亚型,并探讨这些亚型是否与脓毒症及其他危重症状态共享生物学特征。
- 作者提出识别CS分子亚型可丰富未来临床试验设计并促进新疗法发现。
证据类型、等级与局限
- 证据类型:综述(state-of-the-art review)。
- 局限:原文未报告局限性
对床旁实践的改变
- 原文未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Recent clinical and research efforts in cardiogenic shock (CS) have largely focussed on the restoration of the low cardiac output state that is the conditio sine qua non of the clinical syndrome. This approach has failed to translate into improved outcomes, and mortality has remained static at 30-50%. There is an unmet need to better delineate the pathobiology of CS to understand the observed heterogeneity of presentation and treatment effect and to identify novel therapeutic targets. Despite data in other critical illness syndromes, specifically sepsis, the role of dysregulated inflammation and immunity is hitherto poorly described in CS. High-dimensional molecular profiling, particularly through leukocyte transcriptomics, may afford opportunity to better characterise subgroups of patients with shared mechanisms of immune dysregulation. In this state-of-the-art review, we outline the rationale for considering molecular subtypes of CS. We describe how high-dimensional molecular technologies can be used to identify these subtypes, and whether they share biological features with sepsis and other critical illness states. Finally, we propose how the identification of molecular subtypes of patients may enrich future clinical trial design and identification of novel therapies for CS.
参考来源
- Buckel M, Maclean P, Knight JC, et al. Extending the 'host response' paradigm from sepsis to cardiogenic shock: evidence, limitations and opportunities. Crit Care. 2023. PMID: 38012789. doi:10.1186/s13054-023-04752-8
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。